Literature DB >> 18566232

DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis.

Shulamit Batya Wallach-Dayan1, Ariel M Rubinstein, Carla Hand, Raphael Breuer, David Naor.   

Abstract

We have shown recently that cDNA vaccination, using a virtual lymph node, ameliorates experimental allergic encephalomyelitis. Successful cure from mammary tumor requires resolution of local tumor growth and metastases. We have examined whether targeting of CD44 cell surface adhesion molecule by cDNA vaccination plays a role in resolving mammary tumor development. We show here that CD44 cDNA vaccination decreases the tumor mass and metastatic potential in experimental mammary tumor of BALB/c mice. Vaccination of mice, inoculated with the mammary tumors, by cDNA of CD44 variant (CD44v) but not by cDNA of standard CD44, markedly reduced local tumor development and lung metastasis. Concomitantly, transfection of CD44 antisense into a highly metastatic mammary tumor cell line disrupted the CD44 expression of the cells and reduced their ability to establish local tumors as well as metastatic colonies in the lung. Moreover, when CD44v, but not standard CD44 sense cDNA, was transfected into the poorly metastatic cell line, tumor development was markedly enhanced. It is possible therefore that DNA vaccination with a specific CD44v construct could induce an immune resistance to mammary tumor progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566232     DOI: 10.1158/1535-7163.MCT-07-2383

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  13 in total

1.  Prognostic value of CD44 expression in penile squamous cell carcinoma: a pilot study.

Authors:  Daniele Minardi; Guendalina Lucarini; Alessandra Filosa; Antonio Zizzi; Oriana Simonetti; Anna Maria Offidani; Gianluca d'Anzeo; Roberto Di Primio; Rodolfo Montironi; Giovanni Muzzonigro
Journal:  Cell Oncol (Dordr)       Date:  2012-09-13       Impact factor: 6.730

Review 2.  Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.

Authors:  Yongmin Yan; Xiangsheng Zuo; Daoyan Wei
Journal:  Stem Cells Transl Med       Date:  2015-07-01       Impact factor: 6.940

3.  Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44.

Authors:  Anoma Somasunderam; Varatharasa Thiviyanathan; Takemi Tanaka; Xin Li; Muniasamy Neerathilingam; Ganesh Lakshmana Rao Lokesh; Aman Mann; Yang Peng; Mauro Ferrari; Jim Klostergaard; David G Gorenstein
Journal:  Biochemistry       Date:  2010-10-26       Impact factor: 3.162

4.  TIMP-1 deficiency subverts cell-cycle dynamics in murine long-term HSCs.

Authors:  Lara Rossi; Aysegul V Ergen; Margaret A Goodell
Journal:  Blood       Date:  2011-04-26       Impact factor: 22.113

5.  Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.

Authors:  Bryan P Toole
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

6.  Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.

Authors:  Amandine Bemmo; Christel Dias; April A N Rose; Caterina Russo; Peter Siegel; Jacek Majewski
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

Review 7.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

Review 8.  Targeting hyaluronic acid family for cancer chemoprevention and therapy.

Authors:  Vinata B Lokeshwar; Summan Mirza; Andre Jordan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

9.  Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Authors:  Stephen Hiscox; Bedanta Baruha; Chris Smith; Rebecca Bellerby; Lindy Goddard; Nicola Jordan; Zaruhi Poghosyan; Robert I Nicholson; Peter Barrett-Lee; Julia Gee
Journal:  BMC Cancer       Date:  2012-10-06       Impact factor: 4.430

10.  Cell specific CD44 expression in breast cancer requires the interaction of AP-1 and NFκB with a novel cis-element.

Authors:  Shannon M Smith; Li Cai
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.